Literature DB >> 27646856

Risk of diabetic retinopathy at first screen in children at 12 and 13 years of age.

P H Scanlon1, I M Stratton2, M O Bachmann3, C Jones4, G P Leese5.   

Abstract

AIMS: To investigate the relationships between age at diagnosis of diabetes, age at diabetic eye screening and severity of diabetic retinopathy at first and subsequent screenings in children aged 12 or 13 years.
METHODS: Data were extracted from four English screening programmes and from the Scottish, Welsh and Northern Irish programmes on all children with diabetes invited for their first and subsequent screening episodes from the age of 12 years. Retinopathy levels at first and subsequent screens, time from diagnosis of diabetes to first screening and age at diagnosis in years were calculated.
RESULTS: Data were available for 2125 children with diabetes screened for the first time at age 12 or 13 years. In those diagnosed with diabetes at 2 years of age or less, the proportion with retinopathy in one or both eyes was 20% and 11%, respectively, decreasing to 8% and 2% in those diagnosed between 2 and 12 years (P < 0.0001). Only three children (aged 8, 10 and 11 years at diagnosis of diabetes) had images graded with referable retinopathy and, of these, two had non-referable diabetic retinopathy at all subsequent screenings. Of 1703 children with subsequent images, 25 were graded with referable diabetic retinopathy over a mean follow-up of 3.1 years, an incidence rate of 4.7 (95% confidence interval, 3.1-7.0) per 1000 per year.
CONCLUSIONS: In this large cohort of children, the low prevalence and incidence rates of referable diabetic retinopathy suggest that screening earlier than age 12 is not necessary.
© 2016 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

Entities:  

Mesh:

Year:  2016        PMID: 27646856      PMCID: PMC5434868          DOI: 10.1111/dme.13263

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


This is the largest reported study in the literature of baseline levels of diabetic retinopathy in the age group 12 or 13 years. This is the largest reported study showing the rate of progression of diabetic retinopathy in adolescents. Of 2125 children with diabetes screened for the first time at age 12 or 13 years, three were found to have referable disease. The absence of referable disease in subsequent screens in two of the children and of pre‐proliferative changes in the third child suggest that it is unlikely that any treatment is required.

Introduction

Screening for diabetic retinopathy is a highly cost‐effective health initiative and blindness caused by diabetes is lower in populations where a diabetic eye screening programme is established 1, 2, 3. There is a global increase in the incidence of Type 1 diabetes mellitus in children 4, particularly in those aged under 5 years 5. Young children face long pre‐pubertal years of hyperglycaemia, with pre‐pubertal, pubertal and post‐pubertal years contributing 6, 7 to an increased risk of development of microvascular complications of diabetic retinopathy. In 2013–2014, it was reported 8 that there were 26 687 young persons under 25 with diabetes in England and Wales. Annual screening for diabetic retinopathy is recommended in England, Scotland, Wales and Northern Ireland for all those with diabetes aged 12 and above. This was a pragmatic policy decision taken in 2002–2003 because the youngest person reported with sight‐threatening diabetic retinopathy in the literature at that time was aged 11.3 years 9. We report on the relationships between age at diagnosis of diabetes, diabetic retinopathy levels at first screen at either 12 or 13 years of age, and time to development of sight‐threatening diabetic retinopathy after first screen.

Methods

We recruited data for the Four Nations study 10 from seven diabetic retinopathy screening programmes: the whole‐nation programmes in Wales, Scotland and Northern Ireland and four local English programmes (Brighton, Derbyshire, Leeds and Staffordshire). For the present study, one English programme was excluded because no data were available for age at diagnosis of diabetes. Data for all children referred to the eye screening programme, grading results at first screen, and age in years at diagnosis of diabetes were extracted from the screening programme databases. The inclusion criteria were all children aged 12 and 13 years, who attended their first annual digital photographic screening in the UK. There are very few exclusion criteria, such as when a child is terminally ill. In the English NHS Diabetic Eye Screening Programme all images are allocated a retinopathy (R) grade and a maculopathy (M) grade on the basis of the absence, presence and severity of features of diabetic retinopathy found during quality‐assured grading of the retinal images. A mapping exercise was undertaken between the English, Scottish and ETDRS Grading Criteria 10, 11, 12. Referable or sight‐threatening diabetic retinopathy was identified by the presence of features of moderate to severe non‐proliferative, proliferative diabetic retinopathy or maculopathy in at least one eye. Children with images of either or both eyes that could not be assessed were excluded from these analyses. Time from diagnosis of diabetes to first screening and age at diagnosis were calculated. Screening data from both eyes were combined to provide four possible categories of children: no diabetic retinopathy (R1M0) in both eyes; mild non‐proliferative diabetic retinopathy (R1M0) in one eye; mild non‐proliferative diabetic retinopathy (R1M0) in both eyes; referable diabetic retinopathy (R2 or M1) or fast‐track proliferative diabetic retinopathy (R3) – the referable diabetic retinopathy group including the fast‐track proliferative diabetic retinopathy is referred to as sight‐threatening diabetic retinopathy in this article. For survival analyses of time to diabetic retinopathy in children who had at least two retinal screenings, follow‐up was censored at the time of second screening. We estimated binomial confidence intervals for diabetic retinopathy incidence rates. Kaplan–Meier survival curves of time to diabetic retinopathy were plotted, stratified by duration of diabetic retinopathy at first screening. Cox proportional hazards models estimated the hazard ratio for diabetic retinopathy in children by duration of diabetes at first screening.

Results

In total, 2125 children received their first screening at the age of 12 or 13 years. The results of the baseline screen of 2125 children at the age of 12 or 13 years are shown in Table 1. This has been categorized according to the age of diagnosis of diabetes. O the children diagnosed under the age of 2 years, 20.1% had signs of any retinopathy compared with 6.3% of those diagnosed at the age of 10 years.
Table 1

Results of the baseline screen at the age of 12 years or 13 years

Age at diagnosis of diabetesNumber (total = 2125)Number and proportion with any diabetic retinopathy N/total (%)Number and proportion with mild non‐proliferative diabetic retinopathy in one eye N/total (%)Number and proportion with mild non‐proliferative diabetic retinopathy in both eyes N/total (%)Number and proportion with fast track or referable diabetic retinopathy N/total (%)
2 or under16433/164 (20.1)15/164 (9.1)18/164 (11.0)0/164 (0.0)
311822/118 (18.6)18/118 (15.3)4/118 (3.4)0/118 (0.0)
414121/141 (14.9)19/141 (13.5)2/141 (1.4)0/141 (0.0)
513015/130 (11.5)10/130 (7.7) 5/130 (3.8)0 /130 (0.0)
614915/149 (10.1)10 /149 (6.7)5 /149 (3.4)0/149 (0.0)
718121/181 (11.6)17 /181 (9.4) 4/181 (2.2)0 /181 (0.0)
819313/193 (6.7)9/193 (4.7)3/193 (1.6)1/193* (0.5)
922421/224 (9.4)15 /224 (6.7) 6/224 (2.7)0 /224 (0.0)
1027117/271 (6.3)14/271 (5.2)2/271 (0.7)1/271* (0.4)
1129020/290 (6.9)12 /290 (4.1)7 /290 (2.4)1/290* (0.3)
1226422/264 (8.3)17/264 (6.4)5/264 (1.9)0/264 (0.0)

*Three children were reported as having referable retinopathy at first screening.

Results of the baseline screen at the age of 12 years or 13 years *Three children were reported as having referable retinopathy at first screening. Three children were reported as having referable retinopathy at first screening. The first was diagnosed with diabetes at the age of 8 years in 2000, first screened in November 2005 at age 13 years, and approximately annually thereafter until 2012. Referable diabetic retinopathy was recorded at the first screening, followed by referable diabetic retinopathy in 2007, 2009, 2011 and 2012 with possible pre‐proliferative changes (R2), but mild non‐proliferative diabetic retinopathy (NPDR) in both eyes in 2008. The second was diagnosed with diabetes at the age of 10 years in 2004, and first screened in November 2007 and again in 2012. Referable retinopathy (maculopathy – a blot haemorrhage or exudate < 1 disc diameter from the foveal centre) was reported in 2007, but only mild NPDR in one eye was found in 2012. The third was diagnosed with diabetes at the age of 11 years in 2005, and screened in 2006, 2009, 2010 and 2011. The screening result in 2006 reported ‘proliferative retinopathy’ but subsequent screening reported no diabetic retinopathy in 2009 and mild NPDR in one eye in 2010 and 2011. Follow‐up data were available for 1703 children who had baseline gradable images and at least one subsequent set of images. Of these 1703 children, the median age at diagnosis of diabetes was 8 years with an interquartile range (IQR) of 5–11 years; 52% of these children were male. At baseline, 1531 (89.9%) children were graded as having no retinopathy, 129 (7.6%) were graded as having mild NPDR in one eye and 43 (2.5%) were graded as having mild NPDR in both eyes. Of the 1703 children with subsequent images, 16 had a valid screening result at first screen that was not gradable at the second screen but had at least one subsequent gradable image. Of the 129 children with mild NPDR in one eye at first screen, 88 (68.2%) were graded as no diabetic retinopathy, 26 (20.2%) as mild NPDR in one eye and 15 (11.6%) as mild NPDR in both eyes at the second screen. Of the 43 children with mild NPDR in both eyes at first screen, 18 (41.9%) were graded as no diabetic retinopathy, 12 (27.9%) as mild NPDR in one eye and 13(30.3%) as mild NPDR both eyes at the second screen (chi‐squared for trend = 146, P < 0.0001). During subsequent follow‐up visits, 25 children were graded as having sight‐threatening or referable diabetic retinopathy, three of whom were graded as having proliferative diabetic retinopathy. Figure 1 shows the time to sight‐threatening diabetic retinopathy from baseline screen at 12 or 13 years by age of diagnosis of diabetes in these 25 children. The median time from baseline to sight‐threatening diabetic retinopathy was 3.1 years with an IQR of 1.7–4.1 years.
Figure 1

Time to sight‐threatening diabetic retinopathy from baseline screen at 12 or 13 years by age of diagnosis of diabetes. The lines represent the age at which a child was diagnosed with diabetes. The blue line represents children diagnosed with diabetes at 0,1,2,3 or 4 years. The red line represents children diagnosed with diabetes at 5, 6 or 7 years. The green line represents children diagnosed with diabetes at 8, 9 or 10 years. The purple line represents children diagnosed with diabetes at 11 or 12 years.

Time to sight‐threatening diabetic retinopathy from baseline screen at 12 or 13 years by age of diagnosis of diabetes. The lines represent the age at which a child was diagnosed with diabetes. The blue line represents children diagnosed with diabetes at 0,1,2,3 or 4 years. The red line represents children diagnosed with diabetes at 5, 6 or 7 years. The green line represents children diagnosed with diabetes at 8, 9 or 10 years. The purple line represents children diagnosed with diabetes at 11 or 12 years. The results of the Cox proportional hazards model analysis show that those with longer duration of diabetes at baseline screening episode at age 12 or 13 years were at higher risk of progression to referable diabetic retinopathy with a hazard ratio of 1.36 per year [95% CI (95% CI), 1.20 to 1.53). Figure S1 shows the time to referable retinopathy from diagnosis of diabetes.

Conclusion

Since 2002, the UK National Screening Committee, the SIGN Guideline 13 and the NICE guidelines 14, 15 have recommended annual digital photographic screening for all children over the age of 12 years and adults with diabetes, with evidence from studies 16, 17 demonstrating that one‐ and two‐field digital photographic screening could show sensitivities of > 85% against a reference standard of an ophthalmologists examination or seven‐field stereo‐photography. Specificities of 85–95% were also achieved for mydriatic photography 16, 17 and for staged mydriasis 18. The American Academy of Ophthalmology 19 recommends annual ophthalmic examinations beginning 3–5 years after the diagnosis of Type 1 diabetes mellitus. The International Diabetes Federation/International Society for Pediatric and Adolescent Diabetes guideline 20 recommends examination for diabetic retinopathy in Type 1 diabetes from age 11 years and after two years’ diabetes duration, and from diagnosis in Type 2 diabetes. This study provides original evidence supporting the UK recommendations. It found that, although 10% of children have some retinopathy at baseline screening at the age of 12–13 years, only three children (0.17%) were graded as having sight‐threatening diabetic retinopathy. Of the three we identified, it seems likely that none required treatment because only one case was consistently diagnosed as sight‐threatening and this was pre‐proliferative diabetic retinopathy which does not normally require laser treatment. In those diagnosed with diabetes in early childhood, the rate of retinopathy was significantly higher than for those diagnosed later on. The low prevalence and incidence rates in this large cohort of children suggest that earlier screening for sight‐threatening diabetic retinopathy is not necessary in this age group. There may be value in detecting diabetic retinopathy at a mild stage, but only if it could be shown that closer follow‐up in this at‐risk group could reduce the progression rate and the development of complications in these children.

Funding sources

Funding was received from the NHS Diabetic Eye Screening Programme & Scottish Diabetes Retinal Screening Programme.

Competing interests

None declared. Figure S1. Time to referable retinopathy from diagnosis of diabetes. DR, diabetic retinopathy. Click here for additional data file.
  14 in total

1.  Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group.

Authors:  M Karvonen; M Viik-Kajander; E Moltchanova; I Libman; R LaPorte; J Tuomilehto
Journal:  Diabetes Care       Date:  2000-10       Impact factor: 19.112

Review 2.  Screening and prevention of diabetic blindness.

Authors:  E Stefánsson; T Bek; M Porta; N Larsen; J K Kristinsson; E Agardh
Journal:  Acta Ophthalmol Scand       Date:  2000-08

3.  New blindness in diabetes reduced by more than one-third in Stockholm County.

Authors:  L B Bäcklund; P V Algvere; U Rosenqvist
Journal:  Diabet Med       Date:  1997-09       Impact factor: 4.359

4.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

5.  Do all prepubertal years of diabetes duration contribute equally to diabetes complications?

Authors:  Kim C Donaghue; Jan M Fairchild; Maria E Craig; Albert K Chan; Stephen Hing; Lucy R Cutler; Neville J Howard; Martin Silink
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

6.  Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study.

Authors:  A Kernell; I Dedorsson; B Johansson; C P Wickström; J Ludvigsson; T Tuvemo; J Neiderud; K Sjöström; K Malmgren; P Kanulf; L Mellvig; M Gjötterberg; J Sule; L A Persson; L I Larsson; J Aman; G Dahlquist
Journal:  Diabetologia       Date:  1997-03       Impact factor: 10.122

7.  Effect of mydriasis and different field strategies on digital image screening of diabetic eye disease.

Authors:  H Murgatroyd; A Ellingford; A Cox; M Binnie; J D Ellis; C J MacEwen; G P Leese
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

8.  Progression of diabetes retinal status within community screening programs and potential implications for screening intervals.

Authors:  Graham P Leese; Irene M Stratton; Martin Land; Max O Bachmann; Colin Jones; Peter Scanlon; Helen C Looker; Brian Ferguson
Journal:  Diabetes Care       Date:  2014-12-18       Impact factor: 19.112

9.  A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010.

Authors:  Gerald Liew; Michel Michaelides; Catey Bunce
Journal:  BMJ Open       Date:  2014-02-12       Impact factor: 2.692

10.  Screening attendance, age group and diabetic retinopathy level at first screen.

Authors:  P H Scanlon; I M Stratton; G P Leese; M O Bachmann; M Land; C Jones; B Ferguson
Journal:  Diabet Med       Date:  2015-10-06       Impact factor: 4.359

View more
  4 in total

1.  A Cross-Sectional Study of Ocular Changes in Children and Adolescents with Diabetes Mellitus in Selected Health Facilities in Ghana.

Authors:  Vera A Essuman; Naa N Tagoe; Akye Essuman; Benjamin Abaidoo; Josephine Akpalu; Harold A Sackey; Charles F Hayfron-Benjamin; George Asare; Albert G B Amoah; Thomas A Ndanu; Imelda D B Ofori-Adjei; Nana A Barnes; Benedicta L Appiah-Thompson; Winfried M Amoaku
Journal:  Int J Environ Res Public Health       Date:  2022-04-27       Impact factor: 4.614

Review 2.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

3.  17β-Estradiol Promotes Islet Cell Proliferation in a Partial Pancreatectomy Mouse Model.

Authors:  Tingting Wu; Jinyong Xu; Shengchun Xu; Lianzhong Wu; Youyu Zhu; Guangwu Li; Zhenhua Ren
Journal:  J Endocr Soc       Date:  2017-06-05

Review 4.  Vascular Complication in Adolescents With Diabetes Mellitus.

Authors:  Lara E Graves; Kim C Donaghue
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-09       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.